Impact of early pharmacological treatment on cognitive and behavioral outcome after traumatic brain injury in adults: A meta-analysis

Journal of Clinical Psychopharmacology

Volumn 29, Issue 5, 2009, Pages 468-477

  Wheaton, Patricia ^a   Mathias, Jane L ^a   Vink, Robert ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Acute; Adults; Meta analysis; Pharmacological treatment; Traumatic brain injury

Indexed keywords

AMANTADINE; ANATIBANT; DELTIBANT; DESMOPRESSIN; DEXANABINOL; GACYCLIDINE; METHYLPREDNISOLONE; NIMODIPINE; PLACEBO; REPINOTAN; SUPEROXIDE DISMUTASE MACROGOL; TRAXOPRODIL;

BEHAVIOR CHANGE; CLINICAL TRIAL; COGNITION; DRUG EFFECT; GLASGOW COMA SCALE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME;

ADULT; AMANTADINE; BEHAVIOR; BRAIN INJURIES; COGNITION DISORDERS; CONTROLLED CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PEPTIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 70349659167     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181b66f04     Document Type: Review

References (86)

1. Javouhey E, Guerin A-C, Chiron M. Incidence and risk factors for severe traumatic brain injury resulting from road accidents: a population-based study. Accid Anal Prev. 2006;38:225-233.
2. Elovic E, Zafonte R. Prevention. In: Silver JM, McAllister TW, Yudofsky SC, eds. Textbook of Traumatic Brain Injury. Washington, DC: American Psychiatric Publishing Inc; 2005:727-747.
3. Engel DC, Slemmer JE, Vlug AS, et al. Combined effects of mechanical and ischemic injury to cortical cells: secondary ischemia increases damage and decreases effects of neuroprotective agents. Neuropharmacology. 2005;49:985-995.
4. Lee HB, Lyketsos CG, Rao V. Pharmacological management of the psychiatric aspects of traumatic brain injury. Int Rev Psychiatry. 2003;15:359-370.
5. Royo NC, Shimizu S, Schouten JW, et al. Pharmacology of traumatic brain injury. Curr Opin Pharmacol. 2003;3:27-32.
6. Cooper JR, Bloom FE, Roth RH. The Biochemical Basis of Neuropharmacology. Oxford, UK: Oxford University Press; 2003.
7. Webster RA. Neurotransmitters, Drugs and Brain Function. Chichester, England: John Wiley & Sons Ltd; 2003.
8. Novack TA, Dillon MC, Jackson WT. Neurochemical mechanisms in brain injury and treatment: a review. J Clin Exp Neuropsychol. 1996;18:685-706.
9. Mendez DR, Corbett R, Macias C, et al. Total and ionized plasma magnesium concentrations in children after traumatic brain injury. Pediatr Res. 2005;57:347-352.
10. Shimuzu S, Fulp CT, Royo NC, et al. Pharmacotherapy of prevention. In: Silver JM, McAllister TW, Yudofsky SC, eds. Textbook of Traumatic Brain Injury. Washington, DC: American Psychiatric Publishing Inc; 2005:699-726.
11. Guha A. Management of traumatic brain injury: some current evidence and applications. Postgrad Med J. 2004;80:650-653.
12. Dieli J. Review of traumatic brain injury with orthotic considerations. J Prosthet Orthot. 2002;14:31-35.
13. Cawley MJ, Marburger RK, Earl GL. Investigational neuroprotective drugs in traumatic brain injury. J Neurosci Nurs. 1998;30:369-374.
14. Viano D, von Holst H, Gordon E. Serious brain injury from traffic-related causes: priorities for primary prevention. Accid Anal Prev. 1997;29:811-816.
15. Faden AI. Neuroprotection and traumatic brain injury. Arch Neurol. 2001;58:1553-1555.
16. Lee LL, Galo E, Lyeth BG, et al. Neuroprotection in the rat lateral fluid percussion model of traumatic brain injury by SNX-185, an N-type voltage-gated calcium channel blocker. Exp Neurol. 2004;190:70-78.
17. Aoyama N, Katayama Y, Kawamata T, et al. Effects of antioxidant, OPC-14117, on secondary cellular damage and behavioral deficits following cortical contusion in the rat. Brain Res. 2002;934:117-124.
18. Kaplanski J, Pruneau D, Asa I, et al. LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces brain edema and improves long-term neurological function recovery after closed head trauma in rats. J Neurotrauma. 2002;19:953-964.
19. Panikashvili D, Simeonidou C, Ben-Shabat S, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature. 2001;413:527-531.
20. Berman RF, Verweij BH, Muizelaar JP. Neurobehavioral protection by the neuronal calcium channel blocker ziconotide in a model of traumatic diffuse brain injury in rats. J Neurosurg. 2000;93:821-828.
21. Smith DH, Okiyama K, Thomas MJ, et al. Effects of the excitatory amino acid receptor antagonists kynurenate and indole-2-carboxylic acid on behavioral and neurochemical outcome following experimental brain injury. J Neurosci. 1993;13:5383-5392.
22. Smith DH, Okiyama K, Gennarelli TA, et al. Magnesium and ketamine attenuate cognitive dysfunction following experimental brain injury. Neurosci Lett. 1993;157:211-214.
23. Clifton GL, Lyeth B-G, Jenkins LW, et al. Effect of D,alpha-tocopheryl succinate and polyethylene glycol on performance tests after fluid percussion brain injury. J Neurotrauma. 1989;6:71-81.
24. Narayan RK, Michel ME, Group TCTiHIS. Clinical trials in head injury. J Neurotrauma. 2002;19:503-557.
25. Yurkewicz L, Weaver J, Bullock MR, et al. The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury. J Neurotrauma. 2005;22:1428-1443.
26. Lepeintre J-F, D'Arbigny P, Mathe J-F, et al. Neuroprotective effect of gacyclidine: a multicenter double-blind pilot trial in patients with acute traumatic brain injury. Neurochirurgie. 2004;50:83-95.
27. Kelly DF, Goodale DB, Williams J, et al. Propofol in the treatment of moderate and severe head injury: a randomized, prospective double-blinded pilot trial. J Neurosurg. 1999;90:1042-1052.
28. Stewart L, Bullock R, Teasdale GM, et al. First observations of the safety and tolerability of a competitive antagonist to the glutamate NMDA receptor (GCS 19755) in patients with severe head injury. J Neurotrauma. 1999;16:843-850.
29. Temkin NR, Anderson GD, Winn HR, et al. Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial. Lancet Neurol. 2007;6:29-38.
30. Dikmen SS, Machamer JE, Winn HR, et al. Neuropsychological effects of valproate in traumatic brain injury: a randomized trial. Neurology. 2000;54:895-902.
31. Morris GF, Bullock R, Bowers Marshall S, et al. Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. J Neurosurg. 1999;91:737-743.
32. Marshall LF, Maas AIR, Marshall SB, et al. A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury. J Neurosurg. 1998;89:519-525.
33. Young B, Runge JW, Waxman KS, et al. Effects of pegorgotein on neurologic outcome of patients with severe head injury: a multicenter, randomized controlled trial. JAMA. 1996;276:538-543.
34. Muizelaar JP, Marmarou A, Young HF, et al. Improving the outcome of severe head injury with the oxygen radical scavenger polyethylene glycol-conjugated superoxide dismutase: a phase II trial. J Neurosurg. 1993;78:375-382.
35. The European Study Group on Nimodipine in Severe Head Injury. A multicenter trial of the efficacy of nimodipine on outcome after severe head injury. J Neurosurg. 1994;80:797-804.
36. Bailey I, Bell A, Gray J, et al. A randomized trial of nimodipine in severe head injury: HIT 1. J Neurotrauma. 1992;9(suppl 2):S545YS550.
37. Bailey I, Bell A, Gray J, et al. A trial of the effect of nimodipine on outcome after head injury. Acta Neurochir (Wien). 1991;110:97-105.
38. Chahine LM, Chemali Z. Du rire aux larmes: pathological laughing and crying in patients with traumatic brain injury and treatment with lamotrigine. Epilepsy Behav. 2006;8(3):610-615.
39. Chatham-Showalter PE, Netsky Kimmel D. Stimulating consciousness and cognition following severe brain injury: a new potential clinical use for lamotrigine. Brain Inj. 2000;14:997-1001.
40. Azouvi P, Jokic C, Attal N, et al. Carbamazepine in agitation and aggressive behaviour following severe closed-head injury: results of an open trial. Brain Inj. 1999;13:797-804.
41. Chatham-Showalter PE. Carbamazepine for combativeness in acute traumatic brain injury. J Neuropsychiatry Clin Neurosci. 1996;8:96-99.
42. Pillai SV, Kolluri VRS, Mohanty A, et al. Evaluation of nimodipine in the treatment of severe diffuse head injury: a double-blind placebo-controlled trial. Neurol India. 2003;51:361-363.
43. Grumme T, Baethmann A, Kolodziejczyk D, et al. Treatment of patients with severe head injury by triamcinolone: a prospective, controlled multicenter clinical trial of 396 cases. Res Exp Med (Berl). 1995;195:217-229.
44. Hoppe E, Christensen L, Christensen KN. The clinical outcome of patients with severe head injuries, treated with high-dose dexamethasone, hyperventilation and barbituates. Neurochirurgia. 1981;24:17-20.
45. CRASH Trial Collaborators. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injuryVoutcomes at 6 months. Lancet. 2005;365: 1957-1959.
46. Gaab MR, Trost HA, Alcantara A, et al. BUltrahigh[ dexamethasone in acute brain injury: results from a prospective randomized double-blind multicenter trial (GUDHIS*). Zentralbl Neurochir. 1994;55:135-143.
47. Wolf AI, Levi L, Marmarou A, et al. Effect of THAM upon outcome in severe head injury: a randomized prospective clinical trial. J Neurosurg. 1993;78:54-59.
48. Dearden NM, Gibson JS, McDowall DG, et al. Effect of high-dose dexamethasone on outcome from severe head injury. J Neurosurg. 1986;64:81-88.
49. Giannotta SL, Weiss MH, Apuzzo MLJ, et al. High dose glucocorticoids in the management of severe head injury. Neurosurgery. 1984;15:497-501.
50. Braakman R, Schouten HJA, Blaauw-van Dishoeck M, et al. Megadose steroids in severe head injury: Results of a prospective double-blind clinical trial. J Neurosurg. 1983;58:326-330.
51. Saul TG, Ducker TB, Salcman M, et al. Steroids in severe head injury: a prospective randomized clinical trial. J Neurosurg. 1981;54:596-600.
52. Gualtieri CT, Evans RW. Stimulant treatment for the neurobehavioural sequelae of traumatic brain injury. Brain Inj. 1988;2:273-290.
53. Napolitano E, Elovic EP, Qureshi AI. Pharmacological stimulant treatment of neurocognitive and functional deficits after traumatic and non-traumatic brain injury. Med Sci Monit. 2005;11: RA212YRA220.
54. Ohman J, Braakman R, Legout V. Repinotan (BAY X 3702): a 5HT1A agonist in traumatically brain injured patients. J Neurotrauma. 2001;18:1313-1321.
55. McBeath JG, Nanda A. Use of dihydroergotamine in patients with postconcussion syndrome. Headache. 1994;34:148-151.
56. Knoller N, Levi L, Shoshan I, et al. Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Crit Care Med. 2002;30:548-554.
57. Wong GKC, Zhu XL, Poon WS. Beneficial effect of cerebrolysin on moderate and severe head injury patients: result of a cohort study. Acta Neurochir Suppl. 2005;95:59-60.
58. Marmarou A, Guy M, Murphey L, et al. A single dose, three-arm, placebo-controlled, phase 1 study of the bradykinin B2 receptor antagonist Anatibant (LF16-0687Ms) in patients with severe traumatic brain injury. J Neurotrauma. 2005;22:1444-1455.
59. Marmarou A, Nichols J, Burgess J, et al. Effects of the bradykinin antagonist Bradycor (deltibant, CP-1027) in severe traumatic brain injury: Results of a multi-center, randomized, placebo-controlled trial. J Neurotrauma. 1999;16:431-444.
60. Narotam PK, Rodell TC, Nadvi SS, et al. Traumatic brain contusions: a clinical role for the kinin antagonist CP-0127. Acta Neurochir. 1998;140:793-803.
61. Filipova M, Jung M, Krejcova H. Clinical efficacy of 1-desamino-8-D- arginine-vasopressin (DDAVP) in short-term recovery from minor head injury. Hum Psychopharmacol. 1989;4:47-50.
62. Maas AIR, Murray G, Henney H, et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet. 2006;5:38-45.
63. Bohnen NI, Twijnstra A, Jolles J. A controlled trial with vasopressin analogue (DGAVP) on cognitive recovery immediately after head trauma. Neurology. 1993;43:103-106.
64. Silver JM, McAllister TW, Yudofsky SC. Textbook of Traumatic Brain Injury. Washington, DC: American Psychiatric Publishing Inc; 2005.
65. Tilley A. An Introduction to Psychological Research and Statistics. 3rd ed. Brisbane, Australia: Pineapple Press; 1996.
66. Satz P, Forney DL, Zaucha K, et al. Depression, cognition, and functional correlates of recovery outcome after traumatic brain injury. Brain Inj. 1998;12:537-553.
67. Morris SB, DeShon RP. Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs. Psychol Methods. 2002;7:105-125.
68. Jennett B. Development of Glasgow coma and outcome scales. Nepal J Neurosci. 2005;2:24-28.
69. Townsend JT, Ashby FG. Measurement scales and statistics: the misconception misconceived. Psychol Bull. 1984;96:394-401.
70. Gaito J. Measurement scales and statistics: resurgence of an old misconception. Psychol Bull. 1980;87:564-567.
71. Wang S-T, Yu M-L, Wang C-J, et al. Bridging the gap between the pros and cons in treating ordinal scales as interval scales from an analysis point of view. Nurs Res. 1999;48:226-229.
72. Zakzanis KK. Statistics to tell the truth, the whole truth, and nothing but the truth: formulae, illustrative numerical examples, and heuristic interpretation of effect size analyses for neuropsychological researchers. Arch Clin Neuropsychol. 2001;16:653-667.
73. Zakzanis KK, Leach L, Kaplan E. Neuropsychological Differential Diagnosis. Lisse, the Netherlands: Swets & Zeitlinger; 1999.
74. Lipsey MW, Wilson DB. Practical Meta-analysis. Vol 49. Thousand Oaks, CA: Sage Publications Inc; 2001.
75. Cohen J. Statistical Power Analysis for the Behavioural Sciences. New York, NY: Academic Press; 1977.
76. Cohen J. Quantitative methods in psychology: a power primer. Psychol Bull. 1992;112:155-159.
77. Rothstein HR, Sutton AJ, Borenstein M. Publication Bias in Meta-analysis: Prevention, Assessment and Adjustments. Chichester, England: John Wiley & Sons Ltd; 2005.
78. Hunter JE, Schmidt FL. Methods of Meta-analysis: Correcting Error and Bias in Research Findings. 2nd ed. Thousand Oaks, CA: Sage Publications Inc; 2004.
79. Sindhu F, Carpenter L, Seers K. Development of a tool to rate the quality assessment of randomized controlled trials using a Delphi technique. J Adv Nurs. 1997;25:1262-1268.
80. Hedges LV, Olkin I. Statistical Methods for Meta-analysis. Orlando, FL: Academic Press Inc; 1985.
81. Rosenthal R. Writing meta-analytic reviews. Psychol Bull. 1995;118:183-192.
82. Kraus JF, Chu LD. Epidemiology. In: Silver JM, McAllister TW, Yudofsky SC, eds. Textbook of Traumatic Brain Injury. Washington, DC: American Psychiatric Publishing Inc; 2005:3-26.
83. Saniova B, Drobny M, Kneslova L, et al. The outcome of patients with severe head injuries treated with amantadine sulphate. J Neural Transm. 2004;111:511-514.
84. Marion DW. Traumatic Brain Injury. New York, NY: Thieme; 1999.
85. Levin HS. Treatment of postconcussional symptoms with CDP-choline. J Neurol Sci. 1991;103:S39YS42.
86. Teasdale GM, Bailey I, Bell A, et al. The British/Finnish Co-operative Head Injury Trial Group. The effect of nimodipine on outcome after head injury: a prospective randomised control trial. Acta Neurochir Suppl. 1990;51:315-316.